Biomarker approach harnessed in trials of personalized medicine for bladder cancer

Nat Med. 2021 May;27(5):761-763. doi: 10.1038/s41591-021-01300-1.

Authors

Nazli Dizman¹, Luis Meza², Sumanta K Pal³

Affiliations

¹ Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
² City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
³ City of Hope Comprehensive Cancer Center, Duarte, CA, USA. spal@coh.org.

PMID: 33941920
DOI: 10.1038/s41591-021-01300-1

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal
Biomarkers
Carcinoma, Transitional Cell*
Humans
Precision Medicine
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / genetics

Substances

Antibodies, Monoclonal
Biomarkers
durvalumab